Investigation into Boston Scientific Securities Litigation Announced
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy BSX?
Source: Globenewswire
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Boston Scientific, particularly for investors who purchased securities between July 23, 2025, and February 3, 2026, urging them to seek lead plaintiff status by the May 4, 2026 deadline.
- Disappointing Performance: Boston Scientific's February 4, 2026 earnings report revealed that its U.S. electrophysiology (EP) sales fell short of expectations, resulting in a significant net income miss and a 17.6% stock price drop to $75.50 per share, causing substantial losses for investors.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives violated federal securities laws by failing to disclose the unsustainable growth rate of the EP segment, severely undermining investor confidence and impacting market expectations for future performance.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with relevant information, including former employees and shareholders, to contact the firm to support the ongoing class action lawsuit, ensuring that investors' legal rights are upheld.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 72.990
Low
94.00
Averages
108.14
High
132.00
Current: 72.990
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Positioned for Growth Amid Aging Population
- Aging Population Opportunity: Research from the WHO indicates that by 2050, the proportion of people aged 60 and older will rise to 22%, presenting significant market opportunities for Boston Scientific, particularly in the medical device sector.
- Product Line Expansion: Boston Scientific is enhancing its product portfolio in stroke treatment and prevention through the acquisitions of Penumbra and Silk Road Medical, which is expected to further increase its market share among elderly patients.
- Financial Performance and Market Reaction: Despite achieving double-digit revenue and profit growth in its recent earnings report, the conservative guidance for 2026 sales growth led to a stock price drop of over 17%, making the current stock price appear relatively cheap.
- Valuation Attractiveness: With a forward P/E ratio slightly above 22 and a five-year PEG ratio of 0.85, Boston Scientific is considered undervalued, especially given its consistent growth, attracting investor interest.
See More
Class Action Lawsuit Announced for Boston Scientific Investors
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, indicating potential misleading statements by the company that may have caused investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, highlighting a risk-free legal avenue for investors to seek restitution, thereby enhancing investor confidence.
- Background Analysis: The lawsuit alleges that Boston Scientific concealed the unsustainable growth rate of its U.S. Electrophysiology segment while making positive statements, leading investors to misjudge the company's future performance and impacting market confidence.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Boston Scientific Shareholder Class Action Reminder
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Boston Scientific Corporation (NYSE:BSX) stock between July 23, 2025, and February 3, 2026, alleging the company misled investors regarding the reliability of revenue projections.
- Revenue Projection Missteps: The complaint indicates that while Boston Scientific claimed its electrophysiology (EP) market share would grow at “twice the market” rate, it was actually facing new competition that eroded its market share, thereby limiting the company's growth potential.
- Stock Price Plunge: Following the disappointing fourth quarter results released on February 4, 2026, which revealed underperformance in U.S. EP sales, Boston Scientific's stock price plummeted over 17%, from $91.62 per share on February 3 to $75.50, reflecting market disappointment in the company's outlook.
- Shareholder Action Recommendation: Robbins LLP encourages shareholders to participate in the class action, noting that lead plaintiffs can direct the litigation on behalf of the class, while absent members can still be eligible for recovery, highlighting potential governance issues within the company.
See More
Boston Scientific Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: A shareholder has filed a securities class action lawsuit against Boston Scientific on March 6, 2026, for investors who purchased shares between July 23, 2025, and February 3, 2026, alleging misrepresentations regarding the company's U.S. electrophysiology segment, which may have led to investor losses.
- Lawsuit Details: Investors wishing to serve as lead plaintiffs must file papers by May 4, 2026, with the lead plaintiff representing other class members in directing the litigation, although participation in any recovery does not require serving as lead plaintiff.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List,” showcasing its influence and expertise in the legal field through successful litigation of hundreds of class actions.
- Transparent Fee Structure: All representation by the law firm is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to participate in the lawsuit.
See More
Investigation into Boston Scientific Securities Litigation Announced
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Boston Scientific, particularly for investors who purchased securities between July 23, 2025, and February 3, 2026, urging them to seek lead plaintiff status by the May 4, 2026 deadline.
- Disappointing Performance: Boston Scientific's February 4, 2026 earnings report revealed that its U.S. electrophysiology (EP) sales fell short of expectations, resulting in a significant net income miss and a 17.6% stock price drop to $75.50 per share, causing substantial losses for investors.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives violated federal securities laws by failing to disclose the unsustainable growth rate of the EP segment, severely undermining investor confidence and impacting market expectations for future performance.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with relevant information, including former employees and shareholders, to contact the firm to support the ongoing class action lawsuit, ensuring that investors' legal rights are upheld.
See More
IYH ETF 52-Week Price Fluctuation Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.35 and a high of $67.63, with the latest trade at $63.36, indicating relative stability in the current market environment.
- Technical Analysis Tool: Comparing the recent share price to the 200-day moving average provides investors with deeper insights for technical analysis, aiding in more informed investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their potential impact on underlying assets.
See More
Boston Scientific Positioned for Growth Amid Aging Population
- Aging Population Opportunity: Research from the WHO indicates that by 2050, the proportion of people aged 60 and older will rise to 22%, presenting significant market opportunities for Boston Scientific, particularly in the medical device sector.
- Product Line Expansion: Boston Scientific is enhancing its product portfolio in stroke treatment and prevention through the acquisitions of Penumbra and Silk Road Medical, which is expected to further increase its market share among elderly patients.
- Financial Performance and Market Reaction: Despite achieving double-digit revenue and profit growth in its recent earnings report, the conservative guidance for 2026 sales growth led to a stock price drop of over 17%, making the current stock price appear relatively cheap.
- Valuation Attractiveness: With a forward P/E ratio slightly above 22 and a five-year PEG ratio of 0.85, Boston Scientific is considered undervalued, especially given its consistent growth, attracting investor interest.
See More
Class Action Lawsuit Announced for Boston Scientific Investors
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, indicating potential misleading statements by the company that may have caused investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, highlighting a risk-free legal avenue for investors to seek restitution, thereby enhancing investor confidence.
- Background Analysis: The lawsuit alleges that Boston Scientific concealed the unsustainable growth rate of its U.S. Electrophysiology segment while making positive statements, leading investors to misjudge the company's future performance and impacting market confidence.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Boston Scientific Shareholder Class Action Reminder
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Boston Scientific Corporation (NYSE:BSX) stock between July 23, 2025, and February 3, 2026, alleging the company misled investors regarding the reliability of revenue projections.
- Revenue Projection Missteps: The complaint indicates that while Boston Scientific claimed its electrophysiology (EP) market share would grow at “twice the market” rate, it was actually facing new competition that eroded its market share, thereby limiting the company's growth potential.
- Stock Price Plunge: Following the disappointing fourth quarter results released on February 4, 2026, which revealed underperformance in U.S. EP sales, Boston Scientific's stock price plummeted over 17%, from $91.62 per share on February 3 to $75.50, reflecting market disappointment in the company's outlook.
- Shareholder Action Recommendation: Robbins LLP encourages shareholders to participate in the class action, noting that lead plaintiffs can direct the litigation on behalf of the class, while absent members can still be eligible for recovery, highlighting potential governance issues within the company.
See More
Boston Scientific Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: A shareholder has filed a securities class action lawsuit against Boston Scientific on March 6, 2026, for investors who purchased shares between July 23, 2025, and February 3, 2026, alleging misrepresentations regarding the company's U.S. electrophysiology segment, which may have led to investor losses.
- Lawsuit Details: Investors wishing to serve as lead plaintiffs must file papers by May 4, 2026, with the lead plaintiff representing other class members in directing the litigation, although participation in any recovery does not require serving as lead plaintiff.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List,” showcasing its influence and expertise in the legal field through successful litigation of hundreds of class actions.
- Transparent Fee Structure: All representation by the law firm is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to participate in the lawsuit.
See More
Investigation into Boston Scientific Securities Litigation Announced
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Boston Scientific, particularly for investors who purchased securities between July 23, 2025, and February 3, 2026, urging them to seek lead plaintiff status by the May 4, 2026 deadline.
- Disappointing Performance: Boston Scientific's February 4, 2026 earnings report revealed that its U.S. electrophysiology (EP) sales fell short of expectations, resulting in a significant net income miss and a 17.6% stock price drop to $75.50 per share, causing substantial losses for investors.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives violated federal securities laws by failing to disclose the unsustainable growth rate of the EP segment, severely undermining investor confidence and impacting market expectations for future performance.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with relevant information, including former employees and shareholders, to contact the firm to support the ongoing class action lawsuit, ensuring that investors' legal rights are upheld.
See More
IYH ETF 52-Week Price Fluctuation Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.35 and a high of $67.63, with the latest trade at $63.36, indicating relative stability in the current market environment.
- Technical Analysis Tool: Comparing the recent share price to the 200-day moving average provides investors with deeper insights for technical analysis, aiding in more informed investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their potential impact on underlying assets.
See More
